ClinicalTrials.gg
CompletedNCT06049810Updated Aug 17, 2025

IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

A Phase 3 interventional study of IBI112 and IBI112/placebo in Psoriasis, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-17.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
566
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Enrollment
21st of 182
566 · median 171
Started
2023
with 27 others
Phase 3
58 of 206
16 open now
Registered
108th of 206
by date

Among the 206 studies in Psoriasis with a site in China, this one is the 21st largest by enrollment of the 182 interventional ones that give a count, is one of 28 that started in 2023, is one of 58 in phase 3, and was the 108th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of IBI112 in the treatment of participants with moderate to severe psoriasis

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have a diagnosis of plaque-type psoriasis for at least 6 months;
  2. Psoriasis Area and Severity Index (PASI) score of 12 or greater, AND static Physician's Global Assessment (sPGA) score of 3 (moderate) or greater; Psoriasis covering at least 10% of body surface area;
  3. Must be a candidate for either systemic therapy or phototherapy for psoriasis.

Exclusion criteria

Exclusion Criteria:

  1. Has any condition that, in the opinion of the investigator, would make participation not be in the best interest (for example, compromise the well-being) of the participant or that could prevent, limit, or confound the protocol-specified assessments
  2. Participants who have ever received IBI112 or IL-23 inhibitor
  3. History or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
  4. Has any condition that, in the opinion of the investigator, would make participation not be in the best interest of the participant
  5. Is pregnant, nursing, or planning a pregnancy (both men and women) within 6 months following the last administration of the study drug
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
566 participants (actual)

Study arms

  • Experimental
    Group 3

    Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& Dose 1 IBI112 through week 44

    Drug: IBI112

  • Experimental
    Group 4

    Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 through week 44

    Drug: IBI112

  • Experimental
    Group 6

    Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& Dose 1 IBI112 through week 44

    Drug: IBI112

  • Placebo comparator
    Group 5

    Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& placebo through week 44

    Drug: IBI112/placebo

  • Experimental
    Group 1

    Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 through week 44

    Drug: IBI112

  • Placebo comparator
    Group 2

    Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& placebo through week 44

    Drug: IBI112/placebo

Interventions

  • DrugIBI112

    Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& Dose 1 IBI112 through week 44

  • DrugIBI112/placebo

    Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& placebo through week 44 by subcutaneous injection

  • DrugIBI112/placebo

    Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& placebo through week 44

  • DrugIBI112

    Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& Dose 1 IBI112 through week 44

  • DrugIBI112

    Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 through week 44

  • DrugIBI112

    Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 through week 44 by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Percentage of participants with a Psoriasis Area and Severity Index (PASI) 90 Response

    Time frame: Week 56

Secondary outcomes

  1. Percentage of participants with a PASI75 Response

    Time frame: Week 56

  2. Percentage of participants with a PASI100 Response

    Time frame: Week 56

  3. Percentage of participants with a static Investigator's Global Assessment (sIGA) score of 0 or 1

    Time frame: Week 56

  4. Percentage of participants with Dermatology Life Quality Index (DLQI) Score

    Time frame: Week 56

  5. Percentage of participants with a sIGA score of 0

    Time frame: Week 56

  6. Cumulative Maintenance Rate of PASI 90 Response Through Week 56 to Evaluate Loss of a PASI 90 Response

    Time frame: Week 56

  7. Changes of PASI Scores participants who relapse and retreatment

    Time frame: Week 56

  8. Changes of sIGA score in participants who relapse and retreatment

    Time frame: Week 56

07

Study locations

1 site
  • Shanghai Skin Disease Hospital
    Shanghai, Shanghai Municipality 200443, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Apr 2025, 18 months.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 18 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2023
First posted
Sep 22, 2023
StartActual
Oct 10, 2023
Primary completionActual
Apr 29, 2025
CompletionActual
Jul 28, 2025
Last update
Aug 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06049810
Responsible party
Sponsor
First posted
Sep 22, 2023
Start date
Oct 10, 2023
Primary completion
Apr 29, 2025
Completion
Jul 28, 2025
Last update
Aug 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IBI112

Start the discussion